Mesenchymal stem cells exert multiple documented effects on the nervous system, immunomodulation, axon protection, induction of endogenous neurogenesis, and reduction of glial scar formation. Clinical research has covered stroke, multiple sclerosis, Parkinson's disease, and related neurodegenerative conditions across peer-reviewed journals including Cell, Stem Cell Research & Therapy, and Frontiers in Neurology.
Neurodegenerative diseases are a group of conditions where brain and spinal cord cells progressively lose function. Some are triggered by a single event (stroke), others by autoimmune attack (multiple sclerosis), others by processes still not fully understood (Parkinson's, Alzheimer's).
What they share is loss, of motor function, of cognition, of independence. Conventional medicine manages symptoms and slows progression, but rarely targets the underlying neural injury. MSCs exert documented immunomodulatory, neuroprotective, and regenerative effects that make them a candidate for this category of disease.
23C has been developing stem cell protocols for stroke recovery since 2005, combining MSC therapy with specialised support. The goal is not only to help patients cope with symptoms but to promote healing of the original brain lesion, targeting motor function, speech, and cognitive recovery.
An autoimmune condition affecting the myelin sheaths that insulate nerve fibres. MSCs exert immunomodulatory effects on T-cells, B-cells, NK cells, and dendritic cells; may protect axons and improve neuronal survival; and have been studied for their capacity to support remyelination. Research at institutions including the University of Cambridge is ongoing.
A progressive disorder where dopamine-producing neurons in the brain gradually die. MSC therapy is studied for potential neuroprotective effects, reduction of neuroinflammation, and supporting the surrounding neural environment, aiming to slow rather than reverse progression.
A neurodegenerative condition characterised by cognitive decline and neurological damage. MSC therapy is being investigated for its potential to reduce neuroinflammation and support neural tissue, a developing area of research.
For patients recovering from traumatic brain injury, spinal cord injury, or cerebral palsy, MSC therapy has been part of 23C's protocols since 2005. The aim is to support neural repair and reduce scar tissue formation that blocks spontaneous recovery.
Highly potent umbilical cord mesenchymal stem cells delivered by IV infusion. For some neurological conditions, protocols may include intrathecal delivery (via lumbar puncture) to place cells closer to the central nervous system.
Stroke protocols prioritise post-injury neural repair. MS protocols prioritise immune recalibration and myelin support. Parkinson's and Alzheimer's protocols prioritise neuroinflammation reduction. Each is designed around the specific disease biology.
Cell therapy is combined with rehabilitation support, whether physical therapy for stroke recovery, cognitive support for degenerative conditions, or structured symptom monitoring throughout the treatment course.
The following improvements have been reported by past patients. Results vary by individual, improvements cannot be guaranteed.
Neurological conditions rarely have a single treatment path. Share your diagnosis, recent neurological imaging (MRI, CT), medication list, and current neurologist's reports. Our medical team will review whether cell therapy is a fit for your specific disease trajectory.
Request a Case Review